These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22542362)

  • 1. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation.
    Weitz IC; Razavi P; Rochanda L; Zwicker J; Furie B; Manly D; Mackman N; Green R; Liebman HA
    Thromb Res; 2012 Sep; 130(3):361-8. PubMed ID: 22542362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in markers of coagulation and fibrinolysis in patients with Paroxysmal Nocturnal Hemoglobinuria before and during treatment with eculizumab.
    van Bijnen ST; Østerud B; Barteling W; Verbeek-Knobbe K; Willemsen M; van Heerde WL; Muus P
    Thromb Res; 2015 Aug; 136(2):274-81. PubMed ID: 26143713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria.
    Seregina EA; Tsvetaeva NV; Nikulina OF; Zapariy AP; Erasov AV; Gribkova IV; Orel EB; Ataullakhanov FI; Balandina AN
    Blood Cells Mol Dis; 2015 Feb; 54(2):144-50. PubMed ID: 25497169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
    N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
    N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perisurgical induction of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria: its inhibition of surgery-triggered hemolysis and the consequence of subsequent discontinuation.
    Kurita N; Obara N; Fukuda K; Nishikii H; Sato S; Inagawa S; Kurokawa T; Owada Y; Ninomiya H; Chiba S
    Blood Coagul Fibrinolysis; 2013 Sep; 24(6):658-62. PubMed ID: 23917586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab.
    Röth A; Dührsen U
    Eur J Haematol; 2011 Dec; 87(6):473-9. PubMed ID: 21883481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
    Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
    Front Immunol; 2019; 10():1639. PubMed ID: 31379839
    [No Abstract]   [Full Text] [Related]  

  • 10. Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab.
    van Bijnen ST; Wouters D; van Mierlo GJ; Muus P; Zeerleder S
    J Thromb Haemost; 2015 Nov; 13(11):2004-11. PubMed ID: 26333021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
    Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM; Perna F; Selleri C
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab.
    Macrae FL; Peacock-Young B; Bowman P; Baker SR; Quested S; Linton E; Hillmen P; Griffin M; Munir T; Payne D; McKinley C; Clarke D; Newton DJ; Hill A; Ariëns RAS
    Am J Hematol; 2020 Aug; 95(8):944-952. PubMed ID: 32311169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Successful management of orthopedic operations requiring general anesthesia in a PNH patient after introduction of eculizumab].
    Tsutsui M; Gotoh A; Yasuda H; Ono E; Tanaka M; Komatsu N
    Rinsho Ketsueki; 2015 Apr; 56(4):423-7. PubMed ID: 25971274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful use of eculizumab in a pediatric patient treated for paroxysmal nocturnal hemoglobinuria.
    Bauters T; Bordon V; Robays H; Benoit Y; Dhooge C
    J Pediatr Hematol Oncol; 2012 Nov; 34(8):e346-8. PubMed ID: 22767128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria.
    Reiss UM; Schwartz J; Sakamoto KM; Puthenveetil G; Ogawa M; Bedrosian CL; Ware RE
    Pediatr Blood Cancer; 2014 Sep; 61(9):1544-50. PubMed ID: 24777716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
    Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Valentine ME; Khursigara G; Ozawa K; Omine M
    Int J Hematol; 2011 Jan; 93(1):36-46. PubMed ID: 21222185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
    Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
    Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.
    Szer J; Hill A; Weitz IC
    Clin Adv Hematol Oncol; 2012 Nov; 10(11 Suppl 21):1-16. PubMed ID: 23271156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.